U.S. markets closed

Core One Labs Inc. (CLABF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.8825-0.0375 (-4.08%)
At close: 3:58PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.9200
BidN/A x N/A
AskN/A x N/A
Day's Range0.8749 - 0.9600
52 Week Range0.1710 - 1.3000
Avg. Volume78,882
Market Cap64.332M
Beta (5Y Monthly)3.19
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more

      Core One Labs Initiates First Strain Production for Biosynthetic Psilocybin

      VANCOUVER, BC / ACCESSWIRE / February 26, 2021 /Core One Labs Inc. (CSE:COOL), (OTC PINK:CLABF), (Frankfurt:LD62, WKN: A2P8K3) (the "Company" or "Core One") a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce readiness to begin initial biosynthetic psilocybin production trials.


      Core One Labs Finalizes Deal to Acquire Ketamine Infusions Centers of Texas, Entering the US Market for Psychedelic Treatments

      VANCOUVER, BC / ACCESSWIRE / February 24, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62)(WKN:A2P8K3) (the "Company" or "Core One") a research and technology company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy is pleased to announce it has entered into a definitive agreement to acquire (the "Transaction") Ketamine Infusion Centers of Texas Inc.


      Core One Labs Highlights Key Points from International Investor Call

      VANCOUVER, BC / ACCESSWIRE / February 10, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) ("Core One" the "Company") is pleased with the tremendous turnout on the International Investors' Call held earlier today.